1. Home
  2. CGC vs SPRY Comparison

CGC vs SPRY Comparison

Compare CGC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canopy Growth Corporation

CGC

Canopy Growth Corporation

HOLD

Current Price

$0.85

Market Cap

389.2M

Sector

Health Care

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$4.56

Market Cap

404.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGC
SPRY
Founded
N/A
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
389.2M
404.8M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
CGC
SPRY
Price
$0.85
$4.56
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$1.95
★ $22.50
AVG Volume (30 Days)
★ 1.9M
1.4M
Earning Date
11-06-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 84.17
N/A
EPS
★ N/A
N/A
Revenue
$12,759,000.00
★ $84,278,000.00
Revenue This Year
$21.39
$54.14
Revenue Next Year
$8.33
$46.73
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.84
$4.00
52 Week High
$2.38
$13.15

Technical Indicators

Market Signals
Indicator
CGC
SPRY
Relative Strength Index (RSI) 28.16 47.48
Support Level N/A $4.00
Resistance Level $0.98 $8.61
Average True Range (ATR) 0.03 0.26
MACD -0.01 0.09
Stochastic Oscillator 14.60 95.08

Price Performance

Historical Comparison
CGC
SPRY

About CGC Canopy Growth Corporation

Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: